Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Deucravacitinib · Sotyktu

Small molecule · Inhibitor of tyrosine kinase 2 (TYK2) · developed by Bristol

Approved FDA, Sep 2022

BMY Developer

1 Registered trials

What is Deucravacitinib?

Deucravacitinib is a small-molecule inhibitor of tyrosine kinase 2 (TYK2) that binds to the regulatory domain of TYK2, stabilizing an inhibitory interaction that allosterically blocks receptor-mediated TYK2 activation and downstream STAT signaling.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Sotyktu, SOTYKTU
Drug type: Small molecule
Targets: tyrosine kinase 2 (TYK2)
Mechanism: Inhibitor of tyrosine kinase 2 (TYK2)
Pathways: JAK-STAT signaling
Therapy area: Dermatology, Musculoskeletal
Developer: Bristol (BMY)
FDA status: Approved as Sotyktu (September 9, 2022), NDA214958 · FDA label

✅ FDA-approved uses

Moderate-to-severe plaque psoriasis
Active psoriatic arthritis

From the indications section of the FDA label (version of Jun 30, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07116967	Phase 3	Plaque Psoriasis	Recruiting	BMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Plaque Psoriasis

Other drugs acting on TYK2

Baricitinib FDA approved

More from Bristol

Apixaban FDA approved Belatacept FDA approved Ipilimumab FDA approved Lisocabtagene Maraleucel FDA approved Luspatercept FDA approved Mavacamten FDA approved Nab-paclitaxel FDA approved Nivolumab FDA approved Ozanimod FDA approved Relatlimab FDA approved Repotrectinib FDA approved Xanomeline FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BMY page.

Follow BMY, the company behind Deucravacitinib

See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z